权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core C: Medicinal Chemistry and DMPK

核心 C：药物化学和 DMPK

基本信息

批准号：
10522807
负责人：
Thomas D Bannister
金额：
$ 1314.19万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10522807
关键词：
Antiviral Agents Area Biochemical Biological Assay Blood Cells Chemicals Chicago Cluster Analysis Collaborations Cryoelectron Microscopy DNA Development Dose Drug Kinetics Ebola Human Resources Illinois In Vitro Industrialization Lead Libraries Liver Microsomes Metabolism Midwestern United States Minnesota Mississippi Modification Oral Patients Permeability Pharmaceutical Chemistry Pharmaceutical Preparations Philosophy Prevention Problem Solving Property Research Research Personnel Resources Risk Roentgen Rays Role SARS-CoV-2 entry inhibitor SARS-CoV-2 inhibitor Safety Schedule Scientist Series Site Solubility Structure Structure-Activity Relationship Therapeutic Toxic effect Translations Triage Virus Work analog antiviral drug development base clinical development clinical translation computational chemistry design drug candidate drug development drug discovery drug distribution drug metabolism efficacy study experience follow-up helicase high risk high throughput screening in vivo insight interest multidisciplinary novel pandemic disease pathogen pathogenic virus pharmacokinetics and pharmacodynamics preclinical development scaffold screening small molecule structural biology success targeted agent translational potential

项目摘要

Core C – Medicinal Chemistry and DMPK ABSTRACT The discovery of possible drug candidates requires effective collaboration of diverse teams of skilled scientists. Medicinal chemists fulfill a core problem solving role, generally leading efforts to overcome the myriad of obstacles sure to be encountered in any drug discovery campaign. A great many of these hurdles typically involve overcoming deficiencies in drug metabolism and pharmacokinetic (DMPK) properties. Core C of the Midwest AViDD Center centralizes medicinal chemistry and DMPK support functions, with a key role for computational chemistry in impacting hit-to-lead efforts. Core C is comprised of top researchers in their fields, located at 8 different research sites: Scripps-FL, U. Minnesota, Georgia State U, U. Illinois-Chicago, U. Mississippi, N.Y. Blood Center, U.C San Diego, and U.C. Berkeley. The effort seeks not to merely validate new targets and discover “probes” that are ill-suited for development but is focused on the delivery of agents with high translational potential. This philosophy derives in part from the extensive industrial experience of many key personnel in the core. Objectives include the identification and triage of validated hit series, their optimization to validated leads, and finally to the delivery of tractable orally bioavailable drug development candidates in multiple target areas for viruses with high pandemic potential.

核心C -药物化学和DMPK 摘要发现可能的候选药物需要不同的熟练科学家团队的有效合作。药物化学家履行一个核心的问题解决的作用，通常领导努力克服无数的在任何药物发现运动中肯定会遇到的障碍。这些障碍中有很多通常涉及克服药物代谢和药代动力学（DMPK）性质的缺陷。中西部核心C AViDD中心集中了药物化学和DMPK支持功能，在计算方面发挥着关键作用。化学反应影响了点击率。核心C由各自领域的顶尖研究人员组成，位于8 不同的研究地点：Scripps-FL，U。明尼苏达、格鲁吉亚州立大学、伊利诺伊-芝加哥大学纽约州密西西比血液中心，加州大学圣地亚哥分校，和加州大学。伯克利这项工作不仅旨在验证新目标，发现“探针”，不适合发展，但重点是交付代理与高平移势这一理念部分源于许多关键企业的丰富行业经验。核心人员。目标包括识别和分类经验证的命中序列，其优化，经验证的线索，并最终在多个领域中递送易处理的口服生物可利用的药物开发候选物。针对具有高流行潜力的病毒的目标区域。